

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 65660

Title: Biomarkers for gastrointestinal adverse events related to thiopurine therapy

Reviewer's code: 05742997

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: United States

Author's Country/Territory: Italy

Manuscript submission date: 2021-03-12

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-23 20:18

Reviewer performed review: 2021-03-23 21:56

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

I would like to congratulate the authors on their manuscript titled 'Biomarkers for gastrointestinal adverse events related to therapy with thiopurines'. The authors have done a commendable job consolidating evidence that currently exist on biomarkers implicated in GI toxicity. However, I do have a few comments: 1. In the manuscript, the mechanism via which different genes contribute to toxicity should be discussed in more detail. World Journal of Gastroenterology has a wide outreach within the medical community and the readers may not always be Hematology-oncology/Gastroenterology specialists. A detail description of the exact mechanism of toxicity will enhance reader experience. 2. In the clinical implementation section of the manuscript, any current ongoing clinical trials should also be mentioned and referenced. 3. Although the molecular effects of these biomarkers are still relatively unknown, I believe that the readers would highly benefit from the authors take on the possibility of their use in clinical practice and how these agents may be used to guide therapy in the future. 4. The manuscript would need additional language polishing before publication.